HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hanley, A. J.G. Articles by Haffner, S. M. Search for Related Content PubMed PubMed Citation Articles by Hanley, A. J.G. Articles by Haffner, S. M. Social Bookmarking                What's this?

Identification of Subjects with Insulin Resistance and ß-Cell Dysfunction Using Alternative Definitions of the Metabolic Syndrome

¹ Division of Clinical Epidemiology, University of Texas Health Sciences Center, San Antonio, Texas
² Leadership Sinai Centre for Diabetes, Mt. Sinai, Hospital, Toronto, Ontario, Canada
³ Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, North Carolina

Recently, the metabolic syndrome (MetS) has attracted much attention as a risk cluster for cardiovascular disease. Although it is believed that individuals with the MetS have insulin resistance (IR), there are few data using direct measures of IR such as glucose clamps or frequently sampled intravenous glucose tolerance tests (FSIGTTs). We examined associations of MetS with FSIGTT-derived measures of insulin sensitivity and secretion among nondiabetic subjects in the Insulin Resistance Atherosclerosis Study. Two sets of MetS criteria were evaluated: those from the 1999 World Health Organization (WHO) and the 2001 National Cholesterol Education Program (NCEP). Both WHO and NCEP MetS definitions were significantly associated with risk of being in the lowest quartile of directly measured insulin sensitivity (P < 0.0001 for all subjects as well as within ethnic subgroups). However, the associations with WHO-MetS were stronger for all subjects combined (WHO: odds ratio [OR] = 10.2; 95% CI 7.5–13.9; NCEP: OR = 4.6; 3.4–6.2) and in separate analyses of non-Hispanic whites, blacks, and Hispanics. WHO and NCEP MetS definitions were also significantly associated with risk of being in the lowest quartile of insulin sensitivity–adjusted acute insulin response (AIR) and disposition index (DI; all P < 0.01), although the associations were generally weaker than those for insulin sensitivity and there was no difference between the two definitions in all subjects combined (low AIR, WHO: OR = 1.7, 1.2–2.4; NCEP: OR = 1.7, 1.2–2.5). There were, however, a number of ethnic differences, including a stronger association of NCEP-MetS with low AIR among blacks. WHO-MetS was significantly more sensitive than NCEP-MetS in detecting low insulin sensitivity (65.4 vs. 45.6%, respectively; P < 0.0001), with no significant differences in specificity between the definitions (84.4 vs. 84.6%; P = 0.91), although WHO-MetS had a larger area under the receiver operating characteristic curve (75% vs. 65%; P < 0.0001). In conclusion, although both the WHO and NCEP MetS criteria identify nondiabetic individuals with low insulin sensitivity, the associations were notably stronger using the WHO definition. The definitions are generally less useful for identifying those with low AIR or DI, although NCEP-MetS seems to differentiate black subjects with insulin secretion defects.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. J.G. Hanley, L. E. Wagenknecht, A. Festa, R. B. D'Agostino Jr., and S. M. Haffner Alanine Aminotransferase and Directly Measured Insulin Sensitivity in a Multiethnic Cohort: The Insulin Resistance Atherosclerosis Study Diabetes Care, July 1, 2007; 30(7): 1819 - 1827. [Abstract] [Full Text] [PDF]

				J. F. Arenillas, M. A. Moro, and A. Davalos The Metabolic Syndrome and Stroke: Potential Treatment Approaches Stroke, July 1, 2007; 38(7): 2196 - 2203. [Full Text] [PDF]

				P. W. F. Wilson, J. B. Meigs, L. Sullivan, C. S. Fox, D. M. Nathan, and R. B. D'Agostino Sr Prediction of Incident Diabetes Mellitus in Middle-aged Adults: The Framingham Offspring Study Arch Intern Med, May 28, 2007; 167(10): 1068 - 1074. [Abstract] [Full Text] [PDF]

				C. P Chung, I. Avalos, A. Oeser, T. Gebretsadik, A. Shintani, P. Raggi, and C Michael Stein High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors Ann Rheum Dis, February 1, 2007; 66(2): 208 - 214. [Abstract] [Full Text] [PDF]

				R. M. Najarian, L. M. Sullivan, W. B. Kannel, P. W. F. Wilson, R. B. D'Agostino, and P. A. Wolf Metabolic Syndrome Compared With Type 2 Diabetes Mellitus as a Risk Factor for Stroke: The Framingham Offspring Study Arch Intern Med, January 9, 2006; 166(1): 106 - 111. [Abstract] [Full Text] [PDF]

				G. Targher, L. Bertolini, F. Poli, S. Rodella, L. Scala, R. Tessari, L. Zenari, and G. Falezza Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients Diabetes, December 1, 2005; 54(12): 3541 - 3546. [Abstract] [Full Text] [PDF]

				M. K. Rutter, J. B. Meigs, L. M. Sullivan, R. B. D'Agostino Sr, and P. W. Wilson Insulin Resistance, the Metabolic Syndrome, and Incident Cardiovascular Events in the Framingham Offspring Study Diabetes, November 1, 2005; 54(11): 3252 - 3257. [Abstract] [Full Text] [PDF]

				C. H. Saely, S. Aczel, T. Marte, P. Langer, G. Hoefle, and H. Drexel The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5698 - 5703. [Abstract] [Full Text] [PDF]

				J. M. Dekker, C. Girman, T. Rhodes, G. Nijpels, C. D.A. Stehouwer, L. M. Bouter, and R. J. Heine Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn Study Circulation, August 2, 2005; 112(5): 666 - 673. [Abstract] [Full Text] [PDF]

				E. S. Ford Risks for All-Cause Mortality, Cardiovascular Disease, and Diabetes Associated With the Metabolic Syndrome: A summary of the evidence Diabetes Care, July 1, 2005; 28(7): 1769 - 1778. [Abstract] [Full Text] [PDF]

				C. Binnert, M. Genoud, G. Seematter, A. Fekirini, V. Mooser, G. Waeber, and L. Tappy Glucose-Induced Insulin Secretion in Dyslipidemic and Normolipidemic Patients With Normal Glucose Tolerance Diabetes Care, May 1, 2005; 28(5): 1225 - 1227. [Full Text] [PDF]

				G. Bruno, F. Merletti, A. Biggeri, G. Bargero, S. Ferrero, C. Runzo, S. Prina Cerai, G. Pagano, and P. Cavallo-Perin Metabolic Syndrome as a Predictor of All-Cause and Cardiovascular Mortality in Type 2 Diabetes: The Casale Monferrato Study Diabetes Care, November 1, 2004; 27(11): 2689 - 2694. [Abstract] [Full Text] [PDF]

				S. P. Bagby Obesity-Initiated Metabolic Syndrome and the Kidney: A Recipe for Chronic Kidney Disease? J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2775 - 2791. [Full Text] [PDF]

				K. J. Hunt, R. G. Resendez, K. Williams, S. M. Haffner, and M. P. Stern National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study Circulation, September 7, 2004; 110(10): 1251 - 1257. [Abstract] [Full Text] [PDF]

				M. P. Reilly, M. L. Wolfe, T. Rhodes, C. Girman, N. Mehta, and D. J. Rader Measures of Insulin Resistance Add Incremental Value to the Clinical Diagnosis of Metabolic Syndrome in Association With Coronary Atherosclerosis Circulation, August 17, 2004; 110(7): 803 - 809. [Abstract] [Full Text] [PDF]